Correction: Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer

Oncotarget. 2024 Oct 1:15:677-678. doi: 10.18632/oncotarget.28656.

Authors

Chengfei Liu¹, Cameron Armstrong¹, Yezi Zhu^{1

2}, Wei Lou¹, Allen C Gao^{1

2

3}

Affiliations

¹ Department of Urology, University of California Davis, CA, USA.
² Graduate Program in Pharmacology and Toxicology, University of California Davis, CA, USA.
³ UC Davis Comprehensive Cancer Center, University of California Davis, CA, USA.

No abstract available

Publication types

Letter
Published Erratum

MeSH terms

Androgen Receptor Antagonists / pharmacology
Androgen Receptor Antagonists / therapeutic use
Androstenes* / pharmacology
Androstenes* / therapeutic use
Drug Synergism
Humans
Male
Niclosamide* / pharmacology
Niclosamide* / therapeutic use
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / genetics
Prostatic Neoplasms, Castration-Resistant* / metabolism
Prostatic Neoplasms, Castration-Resistant* / pathology
Receptors, Androgen* / genetics
Receptors, Androgen* / metabolism

Substances

Receptors, Androgen
abiraterone
Androstenes
Niclosamide
AR protein, human
Androgen Receptor Antagonists